{"DataElement":{"publicId":"6662204","version":"1","preferredName":"Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Or Myelodysplastic Syndrome Disease or Disorder  First Complete Remission Or Limited Stage Disease Response Indicator","preferredDefinition":"The indicator that describes whether or not AML or ALL in first complete remission or limited stage MDS disease or disorder occurred.","longName":"6662138v1.0:2784450v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6662138","version":"1","preferredName":"Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Or Myelodysplastic Syndrome Disease or Disorder  First Complete Remission Or Limited Stage Disease Response","preferredDefinition":"The pathological and/or clinical changes of Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia in first complete remission or early stage Myelodysplastic Syndrome.","longName":"6662136v1.0:6662147v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6662136","version":"1","preferredName":"Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Or Myelodysplastic Syndrome Disease or Disorder","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"C3171:C3167:C37998:C3247:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"836F411F-5D79-1563-E053-F662850A676A","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6662147","version":"1","preferredName":"First Complete Remission Or Limited Stage Disease Response","preferredDefinition":"Preceding all others in time or space or degree.:The disappearance of all signs of cancer in response to treatment.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Cancer that is localized in its original site of growth, or involves adjacent lymph nodes but has not spread to other anatomic sites.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"6662147v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Limited Stage","conceptCode":"C28065","definition":"Cancer that is localized in its original site of growth, or involves adjacent lymph nodes but has not spread to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8371BFC5-B4A7-3F50-E053-F662850A3D0D","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"ONEDATA","dateModified":"2019-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"836F411F-5D87-1563-E053-F662850A676A","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"KUMMEROA","dateModified":"2019-12-31","changeDescription":". Due to limited definition character length: system generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2784450","version":"1","preferredName":"Yes No Unk ND NA Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes, no, unknown, not done or not applicable.","longName":"Y_N_U_ND_NA_IND","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2567168","version":"1","preferredName":"Yes","longName":"2567168","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":"12/29/2006 - Updated with NCI Thesaurus definition.","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E072-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E07E-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E08A-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Not Applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"56A428C5-E0A2-6CDD-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ALEYR","dateModified":"2008-09-11","deletedIndicator":"No"},{"value":"Not Done","valueDescription":"Not Done: C49484","ValueMeaning":{"publicId":"2579172","version":"1","preferredName":"Not Done: C49484","longName":"2579172","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or completed.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0251-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-04","modifiedBy":"KUMMEROA","dateModified":"2022-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59223A59-341F-0A9E-E044-0003BA3F9857","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-10-13","modifiedBy":"ALEYR","dateModified":"2008-10-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2784449","version":"1","preferredName":"Yes No Unknown Not Done Not Applicable Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Not known, not observed, not recorded, or refused.:Indicates a task, process or examination that has either not been initiated or completed.:Determination that a value is not relevant in the current context.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C49488:C49487:C17998:C49484:C4","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56A428C5-E04C-6CDD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"ONEDATA","dateModified":"2008-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"56A428C5-E05D-6CDD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-11","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-09-11","modifiedBy":"GDEEN","dateModified":"2023-05-12","changeDescription":". Modified def to preferred def per caDSR meeting. No versioning needed. AK 2/8/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PT_ALL_AML_MDS_CR1_IND","type":"VM Alt Name","context":"COG"}],"ReferenceDocuments":[{"name":"At the time of transplant will the recipient have AML or ALL in first complete remission or early stage MDS?","type":"Alternate Question Text","description":"At the time of transplant will the recipient have AML or ALL in first complete remission or early stage MDS?","url":null,"context":"NHLBI"},{"name":"Did the recipient have Acute","type":"Preferred Question Text","description":"Did the recipient have Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia in first complete remission or limited stage Myelodysplastic Syndrome Disease or Disorder?","url":null,"context":"NHLBI"},{"name":"At the time of transplant did the recipient have AML or ALL in first complete remission or early stage MDS?","type":"Alternate Question Text","description":"At the time of transplant did the recipient have AML or ALL in first complete remission or early stage MDS?","url":null,"context":"NHLBI"},{"name":"At the time of transplant did the recipient have AML or ALL in first complete remission or early stage MDS?","type":"Application Standard Question Text","description":"At the time of transplant did the recipient have AML or ALL in first complete remission or early stage MDS?","url":null,"context":"NHLBI"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Is this patient diagnosed with ALL high risk in CR1 for whom transplant is indicated?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is this patient diagnosed with AML in CR1 for whom transplant is indicated?","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8372C1EF-4634-5E84-E053-F662850A82C4","latestVersionIndicator":"Yes","beginDate":"2019-03-06","endDate":null,"createdBy":"MALUMK","dateCreated":"2019-03-06","modifiedBy":"GALITG","dateModified":"2022-03-09","changeDescription":". System generated def displayed as alt def. Added AQT for 2534 due to QT change up. AK 2020-2-20","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}